{
    "nct_id": "NCT03383055",
    "official_title": "CMV-MVA Triplex Vaccine to Enhance Adaptive NK Cell Reconstitution After Autologous Hematopoietic Cell Transplantation in Patients With Lymphoid Malignancies",
    "inclusion_criteria": "* Age > 18 years\n* Lymphoma or multiple myeloma\n* Planned co-enrollment on current (at the time of this study version) or future (opening subsequent to this study) standard of care autologous stem cell transplant protocol.\n\n  * Must meet all eligibility requirements of the co-enrolled parent study\n* Sexually active females of childbearing potential and males with partners of child-bearing potential must agree to use adequate birth control until at least day 100 post-HCT\n* Voluntary written consent signed before performance of any study-related procedure not part of normal medical care\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* CMV immunoglobulin, valganciclovir, ganciclovir, foscarnet, or other anti-CMV therapy within 3 months before the first vaccine is planned. Acyclovir and valacyclovir are allowed.\n* Pregnant or breast feeding. The FDA has not classified this agent into a specified pregnancy category. Females of childbearing potential must have a blood test or urine study within 14 days prior to registration to rule out pregnancy\n* Planned immunotherapy post-HCT. Proteasome inhibitors and/or immunomodulators, such as but not limited to Lenalidomide or Pomalidomide, used for myeloma maintenance are allowed.",
    "miscellaneous_criteria": ""
}